DekaBank Deutsche Girozentrale’s Travere Therapeutics TVTX Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$887K	Hold	30,000	–	–	﹤0.01%	807
2025 Q4	$250K	Hold	30,000	–	–	﹤0.01%	1101
2025 Q3	$719K	Hold	30,000	–	–	﹤0.01%	927
2025 Q2	$444K	Hold	30,000	–	–	﹤0.01%	1006
2025 Q1	$580K	Hold	30,000	–	–	﹤0.01%	946
2024 Q4	$514K	Hold	30,000	–	–	﹤0.01%	1003
2024 Q3	$418K	Hold	30,000	–	–	﹤0.01%	1045
2024 Q2	$257K	Hold	30,000	–	–	﹤0.01%	1116
2024 Q1	$230K	Hold	30,000	–	–	﹤0.01%	1133
2023 Q4	$280K	Buy	+30,000	New	+$218K	﹤0.01%	1147
2023 Q2	–	Sell	-56,400	Closed	-$1.24M	–	1322
2023 Q1	$1.24M	Hold	56,400	–	–	﹤0.01%	825
2022 Q4	$1.19M	Hold	56,400	–	–	﹤0.01%	835
2022 Q3	$1.4M	Hold	56,400	–	–	﹤0.01%	797
2022 Q2	$1.4M	Hold	56,400	–	–	﹤0.01%	799
2022 Q1	$1.42M	Hold	56,400	–	–	﹤0.01%	834
2021 Q4	$1.69M	Sell	56,400 -13,100	-19%	-$369K	﹤0.01%	813
2021 Q3	$1.79M	Buy	69,500 +55,000	+379%	+$1.01M	0.01%	742
2021 Q2	$213K	Hold	14,500	–	–	﹤0.01%	1204
2021 Q1	$351K	Hold	14,500	–	–	﹤0.01%	1085
2020 Q4	$386K	Sell	14,500 -700	-5%	-$16.3K	﹤0.01%	1075
2020 Q3	$280K	Buy	+15,200	New	+$295K	﹤0.01%	1005
2019 Q4	–	Sell	-15,800	Closed	-$188K	–	1224
2019 Q3	$188K	Sell	15,800 -15,800	-50%	-$261K	﹤0.01%	862
2019 Q2	$635K	Buy	31,600 +12,200	+63%	+$241K	﹤0.01%	882
2019 Q1	$575K	Buy	19,400 +3,600	+23%	+$79.6K	﹤0.01%	883
2018 Q4	$352K	Sell	15,800 -3,600	-19%	-$89.6K	﹤0.01%	889
2018 Q3	$575K	Sell	19,400 -500	-3%	-$14.3K	﹤0.01%	903
2018 Q2	$515K	Hold	19,900	–	–	﹤0.01%	899
2018 Q1	$434K	Sell	19,900 -400	-2%	-$9.53K	﹤0.01%	888
2017 Q4	$472K	Hold	20,300	–	–	﹤0.01%	832
2017 Q3	$472K	Hold	20,300	–	–	﹤0.01%	838
2017 Q2	$394K	Hold	20,300	–	–	﹤0.01%	866
2017 Q1	$366K	Sell	20,300 -1,700	-8%	-$33.3K	﹤0.01%	786
2016 Q4	$420K	Buy	22,000 +1,700	+8%	+$34.8K	﹤0.01%	690
2016 Q3	$444K	Hold	20,300	–	–	﹤0.01%	687
2016 Q2	$364K	Buy	20,300 +4,700	+30%	+$76.1K	﹤0.01%	742
2016 Q1	$209K	Sell	15,600 -2,600	-14%	-$39.4K	﹤0.01%	844
2015 Q4	$358K	Buy	18,200 +600	+3%	+$12K	﹤0.01%	755
2015 Q3	$357K	Buy	17,600 +1,400	+9%	+$41.5K	﹤0.01%	754
2015 Q2	$537K	Buy	16,200 +3,800	+31%	+$104K	0.01%	688
2015 Q1	$297K	Buy	+12,400	New	+$189K	﹤0.01%	824

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DekaBank Deutsche Girozentrale's TVTX Position: Q1 2026 in Review

DekaBank Deutsche Girozentrale held its Travere Therapeutics (TVTX) position steady in Q1 2026 at 30,000 shares worth $887K. The position accounts for ﹤0.01% of the portfolio, ranked #807.

DekaBank Deutsche Girozentrale first reported a position in TVTX in Q1 2015 and has held it in 40 quarters since. The position peaked at $1.79M in Q3 2021. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

DekaBank Deutsche Girozentrale held 30,000 shares of Travere Therapeutics worth $887K as of Q1 2026.
DekaBank Deutsche Girozentrale left its Travere Therapeutics share count unchanged in Q1 2026.
Travere Therapeutics made up ﹤0.01% of DekaBank Deutsche Girozentrale's portfolio in Q1 2026, its #807 holding.
DekaBank Deutsche Girozentrale first reported a position in Travere Therapeutics in Q1 2015 and has held it in 40 quarters since.
DekaBank Deutsche Girozentrale's Travere Therapeutics position peaked at $1.79M in Q3 2021.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2026, filed 7 May 2026.